Cardiology

A 1-year interim analysis of a phase 3, multicenter, open-label, 156-week extension study found overall reductions in systolic and diastolic blood pressure with atogepant 60 mg once daily in persons with...

In this expert interview, Deepak L. Bhatt, MD, MPH discusses guideline-based and emerging strategies for reducing recurrent ischemic stroke risk. From dietary interventions and blood pressure control to...

The FDA approved Baxfendy as an adjunctive treatment to lower blood pressure in adults with hypertension not adequately controlled on other antihypertensive medications.

In intermediate-risk pulmonary embolism, catheter-directed fibrinolysis lowered early clinical deterioration vs anticoagulation alone.

In a post hoc analysis of the SURPASS-CVOT randomized clinical trial, researchers found that tirzepatide was associated with fewer cardiorenal events than dulaglutide in high-risk type 2 diabetes.

In SOUL, oral semaglutide was associated with fewer composite heart failure events in patients with type 2 diabetes and baseline heart failure.

A large real-world cohort analysis presented at the American College of Cardiology’s Annual Scientific Session suggests catheter ablation may be associated with improved survival and reduced stroke risk...

A systematic review and meta-analysis presented at the 2026 American College of Cardiology Scientific Session evaluated whether tafamidis was associated with improved survival in patients aged 80 years and...

In a population-based Ontario analysis, COVID-19 vaccination was not associated with increased sudden death risk in healthy people aged 12 to 50.

New reports link SARS-CoV-2 and RSV to persistent cardiopulmonary risk and describe distinct postviral lung and brain changes in a mouse model.